Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 19,71 € ( 165,28 %). Der Median liegt bei 22,40 € ( 201,48 %).
Kaufen |
7 |
Halten |
1
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -8 / 13 |
Beliebteste Broker
News
- 16.09. - 20:05 Uhr
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. » Mehr auf globenewswire.com
- 09.08. - 20:05 Uhr
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,800 shares of the Company's common stock to two new employees and 350,000 shares of the Company's common stock to the newly-hired Chief Operating Officer, Francis Sarena (the “Inducement Grants”) on August 5, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4). » Mehr auf globenewswire.com
- 07.08. - 17:59 Uhr
89bio: Bullish In Light Of Further MOA Being Established By Peer
89bio, Inc. has two phase 3 studies underway, known as ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, which are using pegozafermin to target F2 — F3 and F4 compensated cirrhosis MASH patients respectively. The promise of the two ongoing phase 3 ENLIGHTEN studies is that there was alignment gained with the FDA that each could use an interim analysis endpoint for potential Accelerated Approval. The global non-alcoholic steatohepatitis market is projected to reach $24.26 billion by 2028. » Mehr auf seekingalpha.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 11,18k | 76,53% |
Nettoeinkommen | 44,69 Mio | 27,06% |
EBITDA | 49,77 Mio | 44,91% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 788,50 Mio € |
Anzahl Aktien | 105,91 Mio |
52 Wochen-Hoch/Tief | 15,38 € - 5,89 € |
Dividenden | Nein |
Beta | 1 |
KGV (PE Ratio) | 4,75 |
KGWV (PEG Ratio) | 0,15 |
KBV (PB Ratio) | 1,61 |
KUV (PS Ratio) | 3.761,16 |
Unternehmensprofil
89bio, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung und Vermarktung von Therapien zur Behandlung von Leber- und kardio-metabolischen Erkrankungen konzentriert. Sein führender Produktkandidat ist Pegozafermin, ein glycoPEGyliertes Analogon des Fibroblasten-Wachstumsfaktors 21 zur Behandlung der nichtalkoholischen Steatohepatitis. Das Unternehmen beabsichtigt außerdem, Pegozafermin für die Behandlung von schwerer Hypertriglyceridämie zu entwickeln. 89bio, Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in San Francisco, Kalifornien.
Name | 89BIO INC |
CEO | Rohan Palekar |
Sitz | San Francisco,
ca USA |
Website | |
Industrie | Chemikalien |
Börsengang | 11.11.2019 |
Mitarbeiter | 70 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ETNB |
Assets entdecken
Shareholder von 89BIO INC investieren auch in folgende Assets